ArticleImmunology2007
Mannan-mediated gene delivery for cancer immunotherapy.
Article in Immunology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 60 citations in OpenAlex.
- Natural polysaccharides targeting mitochondrial function for colorectal cancer prevention and treatment: mechanisms and nano-delivery strategies.Chinese medicine · 2026Review
- A multivalent mRNA vaccine elicits robust immune responses and confers protection in a murine model of monkeypox virus infection.Nature communications · 2025Article
- Mannan-decorated STING-activating vaccine carrier for spatial coordinative stimulating antigen-specific immune responses.Fundamental research · 2025Article
- Nanomaterials Application for STING Pathway-Based Tumor Immunotherapy.International journal of nanomedicine · 2025Review
- Recent Advances in Biomedical Applications of Mannans and Xylans.Current drug targets · 2024Review
- Dynamic Imine Bonding Facilitates Mannan Release from a Nanofibrous Peptide Hydrogel.Bioconjugate chemistry · 2023Article
- Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan.Brain sciences · 2021Review
- Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines.Pharmaceutics · 2020Review
- The Long Road of Immunotherapeutics against Multiple Sclerosis.Brain sciences · 2020Article
- Article
- Carbohydrate Conjugates in Vaccine Developments.Frontiers in chemistry · 2020Review
- The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer.Cancers · 2019Article
- On the design principles of peptide-drug conjugates for targeted drug delivery to the malignant tumor site.Beilstein journal of organic chemistry · 2018Review
- Targeting antigens to dendritic cell receptors for vaccine development.Journal of drug delivery · 2013Review
- Antigen delivery to macrophages using liposomal nanoparticles targeting sialoadhesin/CD169.PloS one · 2012Article
- Article
- N-glycan targeted gene delivery to the dendritic cell SIGN receptor.Bioconjugate chemistry · 2010Article
- Fabrication of a novel core-shell gene delivery system based on a brush-like polycation of alpha, beta-poly (L-aspartate-graft-PEI).Pharmaceutical research · 2009Article
- DNA vaccines: developing new strategies to enhance immune responses.Immunologic research · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent years have seen a resurgence in interest in the development of efficient non-viral delivery systems for DNA vaccines and gene therapy. We have previously used oxidized and reduced mannan as carriers for protein delivery to antigen-presenting cells by targeting the receptors that bind mannose, resulting in efficient induction of cellular responses. In the present study, oxidized mannan and reduced mannan were used as receptor-mediated gene transfer ligands for cancer immunotherapy. In vivo studies in C57BL/6 mice showed that injection of DNA encoding ovalbumin (OVA) complexed to oxidized or reduced mannan-poly-L-lysine induced CD8 and CD4 T-cell responses as well as antibody responses leading to protection of mice from OVA+ tumours. Both oxidized and reduced mannan delivery was superior to DNA alone or DNA-poly-L-lysine. These studies demonstrate the potential of oxidized and reduced mannan for efficient receptor-mediated gene delivery in vivo, particularly as DNA vaccines for cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.